Project Grant 2232930
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Quarksen LLC provides funding to develop an affordable, point-of-care diagnostic device for detecting viral and non-viral sexually transmitted infections (STIs) such as chlamydia, gonorrhea, syphilis, HIV, hepatitis C, and trichomoniasis. The project aims to create a device with an array of sensors that can rapidly and accurately detect STI biomarkers from cervical...
- This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to RT Microdx Inc. provides $274,362 to develop a novel molecular diagnostic platform for detecting respiratory diseases like strep throat. The platform aims to provide laboratory-quality accuracy for at-home use by non-healthcare professionals. Key technical objectives include optimizing the sensitivity of the platform's pH-sensitive polymer detection mechanism and ensuring robust performance at...
- Federal Cooperative Agreement Summary Prompt Diagnostics, Inc. received a $1.25M Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), awarded June 15, 2025, with completion targeted for May 31, 2027. The company is developing an automated, multiplexed point-of-care diagnostic platform for rapid detection and quantification of Treponema pallidum infections (syphilis). The solution integrates magnetic...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $304,966 to Kompass Diagnostics Inc. aims to develop a portable, cost-effective diagnostic device that can rapidly detect multiple blood-based biomarkers. The key focus is on enabling rapid, quantitative measurement of reproductive hormones to support time-sensitive clinical decisions in fertility treatments. The research objectives include developing an integrated...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
- Federal Project Grant Award Summary Cleaved Diagnostic Corporation received a $305,000 Small Business Technology Transfer (STTR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) effective October 1, 2025 through September 30, 2026. The company will develop a one-step molecular diagnostic platform utilizing Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 12A (CRISPR-Cas12a) technology to detect...
- This $275,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program supports the development of a label-free, high-resolution, high-throughput protein screening platform called Vibrational Spectroscopy with Metasurface Optics (VISMO). The technology aims to enable simultaneous, minute-scale measurement of millions of protein samples, which would dramatically improve the lengthy and costly cycles...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Teardx, LLC will fund the development of a rapid, point-of-care diagnostic test to accurately detect ocular herpes simplex virus (HSV-1) infections. The project aims to create a user-friendly, minimally invasive sampling tool and assay that can be used by eye specialists and urgent care clinicians to quickly screen for active HSV-1 infections, which are a leading cause...
- This National Science Foundation (NSF) Project Grant award for $380,074, awarded on September 1, 2024, aims to develop a platform for instrument-free, easy-to-interpret quantitative analysis of molecular biomarkers. The project will produce a general methodology adaptable to a range of molecular targets, including potential new agents. The key products to be delivered include: A "yes/no" output for quantitative measurement, enabled through stoichiometry and negative cooperativity-based...
SBIR PHASE I: HYBRID DNA-PROTEIN QUANTIFICATION PLATFORM FOR POINT-OF-CARE DIAGNOSIS OF SYPHILIS AND HUMAN IMMUNODEFICIENCY VIRUSES (HIV) -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT IS THE CREATION OF THE FIRST ALL-IN-ONE AUTOMATED SYPHILIS TEST AVAILABLE AT THE POINT-OF-CARE. THE NUMBER OF SYPHILIS CASES IN THE UNITED STATES HAVE DOUBLED IN THE PAST 5 YEARS WITH A FIVE-FOLD INCREASE IN CONGENITAL SYPHILIS PASSED FROM A PREGNANT MOTHER TO THE FETUS. ANNUAL INFECTIONS NOW ACCOUNT FOR $170 MILLION IN LIFETIME MEDICAL COSTS. THIS LOW-COST, PORTABLE TEST WILL ENABLE CARE PROVIDERS AND OUTREACH EFFORTS TO IMMEDIATELY DIAGNOSE AND TREAT PATIENTS IN A SINGLE VISIT TO HALT THE SPREAD OF SYPHILIS INFECTIONS IN THE MOST VULNERABLE POPULATIONS. SYPHILIS TESTING IN THIS PLATFORM WILL BE READILY COMBINED WITH HYBRID DETECTION OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV) TO STREAMLINE SYPHILIS TESTING WITH EXISTING PROGRAMS FOR HIV DIAGNOSIS AND FURTHER ENCOURAGE UPTAKE OF THIS TEST SOLUTION INTO CLINICAL PRACTICE. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT ADDRESSES THE NEED FOR EASIER SYPHILIS TESTING SOLUTIONS TO PROVIDE COMPREHENSIVE DIAGNOSIS ON-SITE WITH THE PATIENT. SYPHILIS DIAGNOSIS RELIES ON TWO SEPARATE ANTIBODY TESTS, OF WHICH ONE REQUIRES QUANTIFYING ANTIBODY LEVELS WITH A TEDIOUS LABORATORY PROCEDURE CALLED RAPID PLASMA REAGIN (RPR) TO CONFIRM IF THE PATIENT HAS AN ACTIVE INFECTION. THE LACK OF RESOURCES AND PERSONNEL TO CONDUCT RPR TESTING ON-SITE SEVERELY LIMITS THE ABILITY OF PUBLIC HEALTH CLINICS TO EFFECTIVELY DIAGNOSIS SYPHILIS IN A TIMELY MANNER. THIS PROJECT WILL COMBINE BOTH ANTIBODY TESTS INCLUDING QUANTITATIVE RPR INTO AN AUTOMATED CARTRIDGE FOR RAPID AND COMPLETE SYPHILIS DIAGNOSIS AT THE POINT-OF-CARE. THE RESEARCH PROPOSED IN THIS PROJECT WILL DEVELOP MAGNETIC PARTICLE-ENABLED ASSAYS FOR EACH ANTIBODY TEST AND INTEGRATE THE ASSAYS INTO A MULTIPLEXED PLASTIC CARTRIDGE. THESE CARTRIDGES, COMBINED WITH A PORTABLE INSTRUMENT, WILL ENABLE ALL STEPS REQUIRED FOR SYPHILIS DIAGNOSIS TO BE COMPLETED WITHIN MINUTES IN AN AFFORDABLE AND EASY-TO-USE FORMAT. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 6/27/24 | ||
| Not listed | $255.7k | 1/18/23 |